Drugs / PEP223
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00895466 | Oct 2008 → Dec 2009 | prostate cancer | Pepscan Therapeutics | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEP223 | “Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients” NCT00895466 ↗ |
| Modality | Vaccine | “The new drug that will be investigated in this trial is a vaccine.” NCT00895466 ↗ |